Kairos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiopharmaceutical therapies for oncology. Established in 2016 and headquartered in New York, the company aims to harness the precision of radiolabeled compounds to selectively deliver therapeutic radiation to tumor cells while minimizing off-target effects. By pairing novel radionuclides with proprietary targeting agents, Kairos Pharma seeks to expand the scope of radioisotope therapy beyond traditional applications and address key unmet medical needs in cancer treatment.
The company’s lead asset, KAI-101, is a targeted alpha therapy currently in Phase 1 clinical trials for metastatic prostate cancer. KAI-101 couples a high-energy alpha-emitting isotope to a prostate-specific membrane antigen (PSMA)–binding ligand, enabling focused delivery of radiation to malignant tissue. In parallel, Kairos Pharma is advancing KAI-102, a beta-emitting compound designed for advanced breast cancer, and is exploring additional indications across solid tumors. Preclinical studies have demonstrated favorable biodistribution profiles and promising anti-tumor activity for both candidates.
Kairos Pharma conducts its research and manufacturing operations in the United States, with strategic partnerships in Europe to support clinical site networks and regulatory filings. The company collaborates with leading academic centers—such as MD Anderson Cancer Center and the University of Zurich—to leverage expertise in nuclear medicine and oncology. These collaborations facilitate translational research activities, patient enrollment for clinical trials, and the refinement of imaging-based biomarkers to monitor treatment response.
Leadership at Kairos Pharma is anchored by Chief Executive Officer Dr. Karen Lin, who brings over 20 years of experience in radiopharmaceutical development, and Chief Medical Officer Dr. Samuel Ortiz, a recognized expert in nuclear oncology. Supported by a multidisciplinary management team and a board comprising industry veterans and scientific advisors, the company is positioned to advance its pipeline with the goal of delivering new therapeutic options to patients with limited treatment choices.
AI Generated. May Contain Errors.
